Scholar Rock Holding Corp
SRRK44.050USD
+0.430+0.99%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
4.37BMarket Cap
LossP/E TTM
More Details of Scholar Rock Holding Corp Company
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
Scholar Rock Holding Corp Info
Ticker SymbolSRRK
Company nameScholar Rock Holding Corp
IPO dateMay 24, 2018
CEOHallal (David L)
Number of employees196
Security typeOrdinary Share
Fiscal year-endMay 24
Address301 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone18572593860
Websitehttps://scholarrock.com/
Ticker SymbolSRRK
IPO dateMay 24, 2018
CEOHallal (David L)
Company Executives of Scholar Rock Holding Corp
Name
Name/Position
Position
Shareholding
Change
Mr. David L. Hallal
Mr. David L. Hallal
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.60M
-11.36%
Dr. Akshay K. Vaishnaw, M.D., Ph.D.
Dr. Akshay K. Vaishnaw, M.D., Ph.D.
President - Research & Development, Director
President - Research & Development, Director
616.21K
-1.08%
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Chief Financial Officer
Chief Financial Officer
600.00K
--
Ms. Caryn Parlavecchio
Ms. Caryn Parlavecchio
Chief Human Resources Officer
Chief Human Resources Officer
155.46K
-1.38%
Ms. Junlin Ho, J.D.
Ms. Junlin Ho, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
96.29K
+1.19%
Ms. Tracey Sacco
Ms. Tracey Sacco
Chief Commercial Officer
Chief Commercial Officer
22.46K
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
21.07K
+11.85%
Ms. Katie Peng
Ms. Katie Peng
Independent Director
Independent Director
18.27K
-5.22%
Dr. Mo Qatanani, Ph.D.
Dr. Mo Qatanani, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.59K
-18.11%
Mr. Joshua Reed
Mr. Joshua Reed
Independent Director
Independent Director
15.73K
+16.53%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David L. Hallal
Mr. David L. Hallal
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.60M
-11.36%
Dr. Akshay K. Vaishnaw, M.D., Ph.D.
Dr. Akshay K. Vaishnaw, M.D., Ph.D.
President - Research & Development, Director
President - Research & Development, Director
616.21K
-1.08%
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Chief Financial Officer
Chief Financial Officer
600.00K
--
Ms. Caryn Parlavecchio
Ms. Caryn Parlavecchio
Chief Human Resources Officer
Chief Human Resources Officer
155.46K
-1.38%
Ms. Junlin Ho, J.D.
Ms. Junlin Ho, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
96.29K
+1.19%
Ms. Tracey Sacco
Ms. Tracey Sacco
Chief Commercial Officer
Chief Commercial Officer
22.46K
--
Revenue Breakdown
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.69%
Invus Public Equities Advisors, LLC
9.07%
T. Rowe Price Associates, Inc.
6.65%
Samsara BioCapital, LLC
5.69%
BlackRock Institutional Trust Company, N.A.
5.57%
Other
59.34%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.69%
Invus Public Equities Advisors, LLC
9.07%
T. Rowe Price Associates, Inc.
6.65%
Samsara BioCapital, LLC
5.69%
BlackRock Institutional Trust Company, N.A.
5.57%
Other
59.34%
Shareholder Types
Shareholders
Proportion
Investment Advisor
58.97%
Investment Advisor/Hedge Fund
32.88%
Hedge Fund
12.76%
Venture Capital
9.33%
Individual Investor
3.92%
Research Firm
2.77%
Sovereign Wealth Fund
1.15%
Pension Fund
0.99%
Bank and Trust
0.25%
Institutional Shareholding
Updated: 3 hours ago
Updated: 3 hours ago
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
512
121.53M
119.14%
+2.04M
2025Q3
483
118.67M
123.52%
-2.02M
2025Q2
466
118.81M
123.62%
+4.48M
2025Q1
456
113.90M
119.97%
-666.42K
2024Q4
421
111.65M
118.02%
+13.32M
2024Q3
371
94.78M
117.45%
-2.79M
2024Q2
357
92.97M
115.37%
-3.23M
2024Q1
328
91.48M
116.64%
-131.69K
2023Q4
308
87.39M
122.16%
+15.93M
2023Q3
283
62.18M
111.86%
-162.68K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
13.96M
13.69%
+175.20K
+1.27%
Sep 30, 2025
Invus Public Equities Advisors, LLC
9.25M
9.07%
--
--
Sep 30, 2025
T. Rowe Price Associates, Inc.
6.78M
6.65%
-1.88M
-21.72%
Sep 30, 2025
Samsara BioCapital, LLC
5.80M
5.69%
+190.35K
+3.39%
Oct 06, 2025
BlackRock Institutional Trust Company, N.A.
5.68M
5.57%
-20.37K
-0.36%
Sep 30, 2025
The Vanguard Group, Inc.
4.90M
4.8%
+53.33K
+1.10%
Sep 30, 2025
Wellington Management Company, LLP
4.55M
4.46%
+2.52M
+124.50%
Sep 30, 2025
Redmile Group, LLC
3.90M
3.83%
-24.58K
-0.63%
Sep 30, 2025
State Street Investment Management (US)
3.76M
3.69%
+688.81K
+22.41%
Sep 30, 2025
Bellevue Asset Management AG
3.24M
3.18%
+297.24K
+10.09%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
5.43%
Roundhill GLP-1 & Weight Loss ETF
2.04%
State Street SPDR S&P Biotech ETF
1.71%
Amplify Weight Loss Drug & Treatment ETF
1.26%
Tema Heart & Health ETF
0.77%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
Virtus LifeSci Biotech Clinical Trials ETF
0.6%
First Trust Multi-Manager Small Cap Opportunities ETF
0.59%
AltShares Event-Driven ETF
0.53%
ProShares Ultra Nasdaq Biotechnology
0.52%
View more
iShares Neuroscience and Healthcare ETF
Proportion5.43%
Roundhill GLP-1 & Weight Loss ETF
Proportion2.04%
State Street SPDR S&P Biotech ETF
Proportion1.71%
Amplify Weight Loss Drug & Treatment ETF
Proportion1.26%
Tema Heart & Health ETF
Proportion0.77%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.63%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.6%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.59%
AltShares Event-Driven ETF
Proportion0.53%
ProShares Ultra Nasdaq Biotechnology
Proportion0.52%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Scholar Rock Holding Corp?
The top five shareholders of Scholar Rock Holding Corp are:
Fidelity Management & Research Company LLC holds 13.96M shares, accounting for 13.69% of the total shares.
Invus Public Equities Advisors, LLC holds 9.25M shares, accounting for 9.07% of the total shares.
T. Rowe Price Associates, Inc. holds 6.78M shares, accounting for 6.65% of the total shares.
Samsara BioCapital, LLC holds 5.80M shares, accounting for 5.69% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.68M shares, accounting for 5.57% of the total shares.
Fidelity Management & Research Company LLC holds 13.96M shares, accounting for 13.69% of the total shares.
Invus Public Equities Advisors, LLC holds 9.25M shares, accounting for 9.07% of the total shares.
T. Rowe Price Associates, Inc. holds 6.78M shares, accounting for 6.65% of the total shares.
Samsara BioCapital, LLC holds 5.80M shares, accounting for 5.69% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.68M shares, accounting for 5.57% of the total shares.
What are the top three shareholder types of Scholar Rock Holding Corp?
The top three shareholder types of Scholar Rock Holding Corp are:
Fidelity Management & Research Company LLC
Invus Public Equities Advisors, LLC
T. Rowe Price Associates, Inc.
Fidelity Management & Research Company LLC
Invus Public Equities Advisors, LLC
T. Rowe Price Associates, Inc.
How many institutions hold shares of Scholar Rock Holding Corp (SRRK)?
As of 2025Q4, 512 institutions hold shares of Scholar Rock Holding Corp, with a combined market value of approximately 121.53M, accounting for 119.14% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -4.38%.
What is the biggest source of revenue for Scholar Rock Holding Corp?
In FY2024, the -- business generated the highest revenue for Scholar Rock Holding Corp, amounting to -- and accounting for --% of total revenue.
